JP2018512041A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512041A5
JP2018512041A5 JP2017534279A JP2017534279A JP2018512041A5 JP 2018512041 A5 JP2018512041 A5 JP 2018512041A5 JP 2017534279 A JP2017534279 A JP 2017534279A JP 2017534279 A JP2017534279 A JP 2017534279A JP 2018512041 A5 JP2018512041 A5 JP 2018512041A5
Authority
JP
Japan
Prior art keywords
deoxy
nucleotide
nucleic acid
antisense strand
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512041A (ja
JP6865169B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067557 external-priority patent/WO2016106402A1/en
Publication of JP2018512041A publication Critical patent/JP2018512041A/ja
Publication of JP2018512041A5 publication Critical patent/JP2018512041A5/ja
Application granted granted Critical
Publication of JP6865169B2 publication Critical patent/JP6865169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534279A 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤 Active JP6865169B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014266198 2014-12-26
JP2014266198 2014-12-26
US201562184209P 2015-06-24 2015-06-24
US62/184,209 2015-06-24
US201562266668P 2015-12-13 2015-12-13
US62/266,668 2015-12-13
PCT/US2015/067557 WO2016106402A1 (en) 2014-12-26 2015-12-28 Rna interference agents for p21 gene modulation

Publications (3)

Publication Number Publication Date
JP2018512041A JP2018512041A (ja) 2018-05-10
JP2018512041A5 true JP2018512041A5 (OSRAM) 2019-02-14
JP6865169B2 JP6865169B2 (ja) 2021-04-28

Family

ID=56151549

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Country Status (10)

Country Link
US (14) US10264976B2 (OSRAM)
EP (9) EP3236969A4 (OSRAM)
JP (10) JP6730285B2 (OSRAM)
KR (4) KR102527430B1 (OSRAM)
CN (7) CN108064155B (OSRAM)
AU (4) AU2015369596A1 (OSRAM)
BR (2) BR112017013597B1 (OSRAM)
CA (4) CA2972270A1 (OSRAM)
RU (4) RU2756253C2 (OSRAM)
WO (7) WO2016106405A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
PT3236974T (pt) * 2014-12-26 2020-06-01 Nitto Denko Corp Agentes de interferência de rna para modulação génica de gst-pi
CA2990668C (en) 2015-06-24 2024-07-02 Nitto Denko Corporation IONIZABLE COMPOUNDS AND RELATED COMPOSITIONS AND USES
BR112018008344A2 (pt) 2015-12-13 2018-10-30 Nitto Denko Corp molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição
KR102584661B1 (ko) 2016-05-10 2023-10-04 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 염증 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약 및 진단 방법
JP2019508379A (ja) * 2017-02-16 2019-03-28 日東電工株式会社 悪性腫瘍に対する治療方法及び治療用組成物
WO2019090359A1 (en) 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
KR102715821B1 (ko) * 2017-11-09 2024-10-10 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
CN109777798A (zh) * 2017-11-13 2019-05-21 深圳华大生命科学研究院 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN108486011B (zh) * 2018-03-27 2020-05-05 山东大学 一种三联苯化合物、制备方法及其应用
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020009189A1 (ja) * 2018-07-05 2020-01-09 洋司郎 新津 Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
CN112739381A (zh) * 2018-08-22 2021-04-30 日东电工株式会社 使用了hsp47的抑制物质的癌转移抑制
CN112739382A (zh) * 2018-08-22 2021-04-30 日东电工株式会社 使用了hsp47的抑制物质的化疗剂敏感性的增强
PT3880212T (pt) * 2018-11-16 2024-02-08 Nitto Denko Corp Formulação e métodos de administração de rna de interferência para tumores malignos
EP3906930A4 (en) * 2018-12-05 2022-08-24 Nitto Denko Corporation RNAI MOLECULE FOR TREATMENT OF CANCER
EP3909588A4 (en) 2019-01-10 2023-01-04 Osaka University IMMUNO-STIMULATING COMPOSITION
JPWO2020196736A1 (OSRAM) * 2019-03-28 2020-10-01
JP2019116507A (ja) * 2019-04-25 2019-07-18 有限会社オービット Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法
EP3965781A2 (en) * 2019-07-02 2022-03-16 Argonaute Rna Limited Apolipoprotein b antagonist
EP4005602A4 (en) * 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
US20230061751A1 (en) * 2020-01-17 2023-03-02 University Of Massachusetts Universal dynamic pharmacokinetic-modifying anchors
CN112280800B (zh) * 2020-10-19 2022-06-07 上海市东方医院（同济大学附属东方医院） 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用
AU2021411103B2 (en) * 2020-12-28 2025-04-24 1E Therapeutics, Ltd. P21 mrna target areas for silencing
AU2021416356A1 (en) 2020-12-28 2023-08-10 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
JPWO2023210713A1 (OSRAM) * 2022-04-27 2023-11-02
WO2025072649A1 (en) * 2023-09-28 2025-04-03 Nitto Denko Corporation Combination therapy

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005898B1 (ko) 1987-09-21 1997-04-21 젠- 프로우브 인코퍼레이티드 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약
US5204241A (en) 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
CA2174339A1 (en) 1993-10-27 1995-05-04 Lech W. Dudycz 2'-amido and 2'-peptido modified oligonucleotides
DE69633722T2 (de) 1995-06-07 2005-11-03 TELIK, INC., Palo Alto Stoffwechseleffekt von bestimmten glutation analogen
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
JPH10330249A (ja) * 1997-05-30 1998-12-15 Kureha Chem Ind Co Ltd レチノール化合物含有ｈｓｐ４７合成抑制剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2328731A1 (en) 1998-04-16 1999-10-28 Atsushi Imaizumi Glutathione derivatives and dosage forms thereof
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2005019453A2 (en) 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20070083945A1 (en) 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
WO2001088191A1 (en) * 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2004055165A2 (en) 2002-12-13 2004-07-01 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
JP5243789B2 (ja) 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
MX2007002294A (es) 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
JP2008536874A (ja) 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
ES2324128A1 (es) * 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
EP1954820A1 (en) 2005-10-25 2008-08-13 Het Nederlands Kanker Instituut Prediction of local recurrence of breast cancer
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
US20070197460A1 (en) 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
CN101346393B (zh) * 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
EP1948213B1 (en) 2005-11-17 2009-02-04 The Children's Medical Center Corporation Methods to predict and prevent resistance to taxoid compounds
US7729737B2 (en) 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
EP1957044B1 (en) 2005-12-01 2013-03-13 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
KR101320916B1 (ko) * 2006-05-11 2013-10-23 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법
US8067390B2 (en) 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
AU2008270209B2 (en) 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
WO2009029688A2 (en) * 2007-08-27 2009-03-05 Boston Biomedical, Inc. Compositions of asymmetric interfering rna and uses thereof
WO2009033284A1 (en) * 2007-09-14 2009-03-19 Mcmaster University Inhibitors of collagen biosynthesis as anti-tumor agents
CA2715796C (en) * 2008-03-06 2015-04-28 Rottapharm S.P.A. 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
EP2321414B1 (en) 2008-07-25 2018-01-10 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
KR20110051214A (ko) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
DK2509991T3 (en) 2009-12-09 2015-12-21 Nitto Denko Corp MODULATION OF HSP47 EXPRESSION
CN102859004A (zh) 2010-02-24 2013-01-02 波蒂塞克股份有限公司 确定基因-营养物的相互作用的方法
US20130004494A1 (en) * 2010-03-12 2013-01-03 Ellen Heber-Katz Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration
US8372819B2 (en) 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
AU2011249406B2 (en) 2010-05-06 2015-05-14 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
AU2011307259A1 (en) 2010-09-30 2013-05-02 Nitto Denko Corporation Modulation of TIMP1 and TIMP2 expression
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
CN107082747B (zh) * 2011-06-08 2020-11-20 日东电工株式会社 用于定向药物输送和增强siRNA活性的化合物
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
ES2708932T3 (es) * 2011-06-21 2019-04-12 Nitto Denko Corp Agente inductor de apoptosis
CN102896619B (zh) * 2011-07-26 2015-04-22 苏州宝时得电动工具有限公司 动力工具及其操作方法
WO2013066485A2 (en) * 2011-08-31 2013-05-10 Asea Alexzander A Compositions and methods for treatment of metastatic cancer
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9631192B2 (en) * 2011-11-17 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
AU2013262972A1 (en) * 2012-05-16 2014-12-11 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
TR201816986T4 (tr) 2012-06-08 2019-01-21 Nitto Denko Corp Terapötik ajan iletim formülasyonlarına yönelik lipitler.
WO2013192364A1 (en) 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
HK1209639A1 (en) * 2012-07-02 2016-04-08 Fibrostatin, S.L. Gpbp-1 inhibition and its therapeutic use
US9708607B2 (en) * 2012-08-03 2017-07-18 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
CN103695421B (zh) 2013-12-09 2016-06-15 浙江大学 一种特异抑制p21基因表达的siRNA及其应用
WO2016104588A1 (ja) * 2014-12-26 2016-06-30 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
BR112018008344A2 (pt) * 2015-12-13 2018-10-30 Nitto Denko Corp molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição
JP6899201B2 (ja) 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Similar Documents

Publication Publication Date Title
JP2018512041A5 (OSRAM)
JP2018512110A5 (OSRAM)
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
Morris siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code
JP2018512060A5 (OSRAM)
JP2018513668A5 (OSRAM)
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
JP2016116520A5 (OSRAM)
JP2018507711A5 (OSRAM)
RU2017132895A (ru) Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
JP2014527401A5 (OSRAM)
CN110944675A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
Pasternak et al. Unlocked nucleic acid–an RNA modification with broad potential
JP2013226147A5 (OSRAM)
JP2017537626A5 (OSRAM)
JP2017079776A5 (OSRAM)
JP2013511990A5 (OSRAM)
EA201690274A1 (ru) Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
JP2013535212A5 (OSRAM)
JP2016522674A5 (OSRAM)
JP2018519835A5 (OSRAM)
JP2016520310A5 (OSRAM)
JP2015511821A5 (OSRAM)
JP2012223202A5 (OSRAM)
EP2844757A2 (en) Organic compositions to treat kras-related diseases